Matthew Lorenzi
Vice President, Lung Cancer Disease
DIS Private Enterprise
Greece
Biography
Vice President, Lung Cancer Disease Collaborate with a talented research and development group focused on small molecule and biologics-based oncology drug discovery for lung cancer and other malignancies. Our team is delivering innovative next generation cancer immunotherapies and targeted agents to patients in dire need of new therapies. Productive pharmaceutical experience in: -Establishing an R&D strategy and delivering an innovative portfolio against it -Strong productive people management and matrix management experience -Biologic & small molecule program generation and clinical advancement -Translational research experience to drive new combination and patient selection strategies -Search, evaluation & diligence of external biotech opportunities and pharma partnerships -Implementation of pre-clinical & clinical academic collaborations -Identification & execution of oncology strategic initiatives -Clinical development lead experience for biologic & small molecule agents for Phase I/II trials
Research Interest
Collaborate with a talented research and development group focused on small molecule and biologics-based oncology drug discovery for lung cancer and other malignancies. Our team is delivering innovative next generation cancer immunotherapies and targeted agents to patients in dire need of new therapies. Productive pharmaceutical experience in: -Establishing an R&D strategy and delivering an innovative portfolio against it -Strong productive people management and matrix management experience -Biologic & small molecule program generation and clinical advancement -Translational research experience to drive new combination and patient selection strategies -Search, evaluation & diligence of external biotech opportunities and pharma partnerships -Implementation of pre-clinical & clinical academic collaborations -Identification & execution of oncology strategic initiatives -Clinical development lead experience for biologic & small molecule agents for Phase I/II trials